Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 8/20 | 0.46 |
| ▸ | MAOA | P21397 | 6/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA5A | P35218 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3031742 | 1.00 | MAOB (0.46) | MAOBMAOAHRH3GRIN1GRIN2B | |
| SCHEMBL3031740 | 1.00 | MAOB (0.46) | MAOBMAOAHRH3GRIN1GRIN2B | |
| SCHEMBL3024731 | 0.91 | MAOB (0.46) | MAOBMAOAHRH3CA2CA5A | |
| SCHEMBL3024735 | 0.91 | MAOB (0.46) | MAOBMAOAHRH3CA2CA5A | |
| SCHEMBL3024728 | 0.91 | MAOB (0.46) | MAOBMAOAHRH3CA2CA5A | |
| SCHEMBL3018527 | 0.78 | CHRNB2 (0.47) | CA2 | |
| SCHEMBL3018524 | 0.78 | CHRNB2 (0.47) | CA2 | |
| SCHEMBL3018337 | 0.78 | GRIN1 (0.48) | MAOBMAOAHRH3GRIN1GRIN2B | |
| SCHEMBL3018340 | 0.78 | GRIN1 (0.48) | MAOBMAOAHRH3GRIN1GRIN2B | |
| SCHEMBL3018338 | 0.78 | GRIN1 (0.48) | MAOBMAOAHRH3GRIN1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100210680-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES | N.V. ORGANON | 2010-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210680-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES | TPH1, HTR2C, TPH2 | MAOB 21/4885MAOA 26/4885HRH3 1337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.